Erlotinib is an FDA-approved oral HER1/EGFR tyrosine kinase inhibitor that blocks tumor cell division, produces cell cycle arrest, and initiates programmed cell death in EGFR-overexpressing human tumor cells [45]. The gene discussed is EGFR; the disease is neoplasm.